Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma
Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma
复制标题
DOI：
10.1111/j.1349-7006.2009.01224.x
复制
发表时间：
2009-09-01
期刊：
影响因子：
5.7
通讯作者：
Xie, Dan
中科院分区：
文献类型：
--
作者：
He, Li-Ru;Liu, Meng-Zhong;Xie, Dan
AIB1(在乳腺癌中扩增)在食管鳞癌(ESCC)中经常过表达，但AIB1在放化疗(CRT)敏感性中的意义及其对预后的影响尚不清楚。本研究采用免疫组织化学方法检测了98例接受CRT治疗的原发ESCC患者活检标本中AIB1的表达。有63/98(64.3%)的食管癌AIB1过表达。AIB1过表达与远处淋巴结转移显著相关(P=0.011)，而与区域淋巴结转移无关。在M0亚组中，AIB1在T4期的表达高于T2-3期(66.7%vs38.5%，P=0.031)。此外，AIB1表达是唯一与CRT疗效显著相关的因素，在CRT耐药组中AIB1过度表达的频率高于CRT有效组(86.5%vs50.8%，P<；0.001)。单因素分析显示，AIB1过表达与无进展生存期(PFS)差(P<；0.001)和疾病特异性生存期(DSS)差(P<；0.001)相关。此外，AIB1的表达可以将患者的生存期分为T2-3期、T4期、N1期和M0期(P<；0.05)，在CRT有效组(P<；0.05)中，AIB1的过度表达和CRT抵抗被评估为PFS和DSS的显著独立预后因素。这些结果表明，AIB1的过度表达是预测CRT耐药的有用指标，也是ESCC患者预后不良的独立分子标志物。(《癌症科学》2009；100：1591-1596)。
AIB1 (amplified in breast cancer 1) is frequently overexpressed in esophageal squamous cell carcinoma (ESCC), but the significance of AIB1 expression in chemoradiotherapy (CRT) sensitivity and its effect on prognosis are still unclear. In this study, the expression of AIB1 was examined by immunohistochemistry in 98 biopsy specimens of primary ESCC patients treated with definitive CRT. AIB1 overexpression was found in 63/98 (64.3%) of the ESCCs. There was a significant association between AIB1 overexpression and distant lymph node metastases (P = 0.011), but not regional lymph node metastases. In the M0 subgroup, overexpression of AIB1 was observed more frequently in stage T4 than in stage T2-3 (66.7% vs 38.5%, P = 0.031). In addition, AIB1 expression was the only factor that showed a significant correlation with CRT response, in which overexpression of AIB1 was observed more frequently in the CRT resistant group than in the CRT effective group (86.5% vs 50.8%, P < 0.001). Univariate analysis revealed that AIB1 overexpression was associated with poor progression-free survival (PFS) (P < 0.001) and poor disease-specific survival (DSS) (P < 0.001). Furthermore, AIB1 expression could stratify patient survival in stages T2-3, T4, N1, and M0 (P < 0.05), as well as in the CRT effective group (P < 0.05), and AIB1 overexpression and CRT resistance were evaluated as significant independent prognostic factors for both PFS and DSS in multivariate analysis. These findings suggest that overexpression of AIB1 is a useful predictor of CRT resistance and an independent molecular marker of poor prognosis for ESCC patients. (Cancer Sci 2009; 100: 1591-1596).